DEF: Standard BioTools Seeks Stockholder Approval for Equity Incentive Plan Amendment

Standard BioTools is asking stockholders to approve an amendment to its 2011 Equity Incentive Plan to increase the number of shares available for issuance by 17,400,000.

Summary

• Standard BioTools is holding its 2025 annual meeting of stockholders on June 18, 2025, to vote on several proposals.
• One key proposal is to approve an amendment to the company's Amended and Restated 2011 Equity Incentive Plan to increase the number of shares of common stock available for issuance by 17,400,000 shares.
• The board of directors recommends voting in favor of this amendment to attract and retain talent and align employee and stockholder interests.
• Other proposals include electing two Class III directors, providing an advisory vote on executive compensation, and ratifying the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The board recommends voting for all director nominees, the advisory vote on executive compensation, and the ratification of the accounting firm appointment.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive tone due to the board's recommendations and expressions of gratitude.

Positives

• The proposed amendment to the equity incentive plan aims to attract and retain talented personnel.
• Equity awards help align the interests of executives and employees with those of stockholders.
• The company emphasizes variable pay tied to financial results and stock performance.
• The company maintains a clawback policy and anti-hedging/anti-pledging policies.
• The company uses an independent compensation consultant.

Negatives

• Approving the amendment will increase the potential dilution for current shareholders.
• The company's annual share usage, or burn rate, under its equity compensation program for the last three years was 9,973,647 in 2022, 4,147,543 in 2023 and 15,434,378 in 2024.
• The dilutive impact of the additional 17,400,000 shares that would be available for issuance under the A&R 2011 Plan would increase the overhang percentage by approximately five percentage points to approximately 22.2%.

Risks

• If the amendment is not approved, the company may struggle to attract and retain key personnel.
• The company's future success depends on its ability to attract and retain qualified employees.
• The company's equity grant practices are expected to be between the 50th and 75th percentiles of its peer group, which could be seen as aggressive by some investors.
• The company's overhang is expected to be between the 50th and 75th percentiles of its peer group, which could be seen as aggressive by some investors.

Future Outlook

The company aims to improve operational efficiency, realize cost synergies, and capitalize on expanded revenue opportunities to deliver profitable growth and long-term stockholder value.

Management Comments

• Michael Egholm, Ph.D., President & Chief Executive Officer, expressed gratitude for stockholders' continued support and looked forward to seeing them at the Annual Meeting.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors beyond mentioning the peer group used for compensation benchmarking.

Comparison to Industry Standards

• The company benchmarks executive compensation against a peer group of publicly traded companies in the Life Science Tools & Services, Diagnostics, Medical Devices, and certain Biotechnology and Healthcare sectors.
• The peer group includes companies such as 10x Genomics, Adaptive Biotechnologies, Azenta, CareDx, Castle Biosciences, Cryoport, Cytek Biosciences, Guardant Health, Maravai LifeSciences Holdings, NeoGenomics, OraSure Technologies, Pacific Biosciences of California, Quanterix Corporation, Surmodics, Twist Bioscience Corporation and Veracyte.
• The company's burn rate and overhang are expected to be between the 50th and 75th percentiles of its peer group.

Related Party Transactions

• On March 18, 2024, the Company entered into an exchange agreement (the Exchange Agreement) with the Casdin Private Growth Equity Fund II, L.P. and Casdin Partners Master Fund, L.P. (collectively, Casdin) and Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP (collectively, Viking and, together with Casdin, the Investors and individually, an Investor) Pursuant to the Exchange Agreement, the Investors exchanged (the Exchange) an aggregate of (i) 127,780 shares of Series B-1 Convertible Preferred Stock (the Series B-1 Preferred Stock), and (ii) 127,779 shares of Series B-2 Convertible Preferred Stock (the Series B-2 Preferred Stock and, together with the Series B-1 Preferred Stock, the Series B Preferred Stock) representing all of the outstanding shares of Series B Preferred Stock, for an aggregate of 92,930,553 shares of common stock issued by the Company.
• The Company previously entered into a license agreement with PerkinElmer Health Sciences, Inc. (now Revvity Health Sciences, Inc. (Revvity)) pursuant to which the Company granted Revvity a worldwide, non-exclusive, fully paid-up license to certain patents (the Patents) in fields other than (i) inductively coupled plasma-based mass analysis of atomic elements associated with a biological material, including any elements that are unnaturally bound, directly or indirectly, to such biological material (Mass Analysis) and (ii) the development, design, manufacture, and use of equipment or associated reagents for such Mass Analysis.

Stakeholder Impact

• Approval of the equity incentive plan amendment could impact employee morale and retention.
• The outcome of the advisory vote on executive compensation may influence future compensation decisions.
• The ratification of the accounting firm appointment ensures continued financial oversight.

Next Steps

• Stockholders are urged to vote promptly on the proposals.
• The company will announce preliminary voting results at the Annual Meeting and disclose final results in a Form 8-K filed with the SEC.

Key Dates

Keywords

equity incentive plan, proxy statement, stockholders, compensation, directors, governance, Standard BioTools